Empagliflozin, a vital medication that was previously expensive, will soon be made available by domestic pharmaceutical companies at much-reduced pricing, which is good news for the millions of indians who suffer from diabetes. The cost of the medication would decrease from Rs 60 per tablet to Rs 9 starting on march 11. Millions of people with diabetes are expected to benefit greatly from this action.
This comes as indian companies are now able to market the medicine under their own brands after the German pharmaceutical giant Boehringer Ingelheim's patent expired on march 11. Prominent pharmaceutical firms like Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin are among them. Notably, Mankind Pharma intends to sell the medication for 90% less than the pioneering business.
In the treatment of diabetes and its related disorders, including heart disease and chronic kidney disease, empagliflozin is essential. In india, more than 10.1 crore individuals have diabetes, and many of them must pay for their own medications. Patients benefit greatly from this price reduction in terms of their financial situation.
Experts stress that empagliflozin is essential for postponing renal failure and preventing heart failure. But in the past, accessibility has been hampered by its high cost. Millions of people stand to gain a great deal from the more reasonably priced solutions offered by indian businesses.
The Times of india reports that Boehringer Ingelheim has sold three branded Empagliflozin medications to Torrent Pharmaceuticals. Mankind Pharma credits the use of premium, USFDA-certified raw materials and the production of its Active Pharmaceutical Ingredient (API) enabling it to further cut expenses.
Diabetes has a significant financial impact in india, and patients frequently have to pay for their own medications due to a lack of insurance coverage. For diabetes people nationwide, the lower cost of empagliflozin is a welcome comfort.
This comes as indian companies are now able to market the medicine under their own brands after the German pharmaceutical giant Boehringer Ingelheim's patent expired on march 11. Prominent pharmaceutical firms like Mankind Pharma, Torrent, Alkem, Dr. Reddy, and Lupin are among them. Notably, Mankind Pharma intends to sell the medication for 90% less than the pioneering business.
In the treatment of diabetes and its related disorders, including heart disease and chronic kidney disease, empagliflozin is essential. In india, more than 10.1 crore individuals have diabetes, and many of them must pay for their own medications. Patients benefit greatly from this price reduction in terms of their financial situation.
Experts stress that empagliflozin is essential for postponing renal failure and preventing heart failure. But in the past, accessibility has been hampered by its high cost. Millions of people stand to gain a great deal from the more reasonably priced solutions offered by indian businesses.
The Times of india reports that Boehringer Ingelheim has sold three branded Empagliflozin medications to Torrent Pharmaceuticals. Mankind Pharma credits the use of premium, USFDA-certified raw materials and the production of its Active Pharmaceutical Ingredient (API) enabling it to further cut expenses.
Diabetes has a significant financial impact in india, and patients frequently have to pay for their own medications due to a lack of insurance coverage. For diabetes people nationwide, the lower cost of empagliflozin is a welcome comfort.
click and follow Indiaherald WhatsApp channel